Bevacizumab for recurrent ependymoma

por Green, R M., Cloughesy, T F., Stupp, R, DeAngelis, L M., Woyshner, E A., Ney, D E., Lassman, A B.
Publicado 2009

Isolated Diffusion Restriction Precedes the Development of Enhancing Tumor in a Subset of Patients with Glioblastoma

por Gupta, A., Young, R.J., Karimi, S., Sood, S., Zhang, Z., Mo, Q., Gutin, P.H., Holodny, A.I., Lassman, A.B.
Publicado 2011

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

por Iwamoto, F M., Abrey, L E., Beal, K, Gutin, P H., Rosenblum, M K., Reuter, V E., DeAngelis, L M., Lassman, A B.
Publicado 2009

Correction to: (18)F-Fluciclovine ((18)F-FACBC) PET imaging of recurrent brain tumors

por Michaud, Laure, Beattie, B. J., Akhurst, T., Dunphy, M., Zanzonico, P., Finn, R., Mauguen, A., Schöder, H., Weber, W. A., Lassman, A. B., Blasberg, R.
Publicado en Eur J Nucl Med Mol Imaging (2019)

(18)F-Fluciclovine ((18)F-FACBC) PET imaging of recurrent brain tumors

por Michaud, Laure, Beattie, B. J., Akhurst, T., Dunphy, M., Zanzonico, P., Finn, R., Mauguen, A., Schöder, H., Weber, W. A., Lassman, A. B., Blasberg, R.
Publicado en Eur J Nucl Med Mol Imaging (2019)

OS07.5 Interim analysis data from Phase 2 study on efficacy, safety & intratumoral pharmacokinetics of oral Selinexor (KPT-330) in patients with recurrent glioblastoma (GBM)

por Lassman, A. B., Bent, M. J. V. D., Wen, P. Y., Walenkamp, A., Plotkin, S., Kung, A., Gardner, H., Shacham, S., Chudnovsky, A., Mau-Sorensen, P. M.
Publicado en Neuro Oncol (2017)

P06.02 Transcriptional profiling to identify determinants associated with response to ABT-414 in patients with glioblastoma

por van den Bent, M., Gan, H., Reardon, D. A., Papadopoulos, K. P., Merrell, R., Kumthekar, P., Roberts-Rapp, L., Holen, K., Ansell, P., Lassman, A. B.
Publicado en Neuro Oncol (2016)

P08.19 Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM)

por van den Bent, M., Gan, H. K., Lassman, A. B., Kumthekar, P., Butowski, N., Lwin, Z., Nabors, L. B., Simes, J., Holen, K., Reardon, D. A.
Publicado en Neuro Oncol (2016)

P01.071 Genomic profiling identifies tubulin mutations that may predict response to depatuxizumab mafodotin in patients with glioblastoma

por Lassman, A B, Roberts-Rapp, L, He, L, Lu, X, Zha, Z, Bhathena, A, Ansell, P J, Gan, H K, Scott, A M, van den Bent, M
Publicado en Neuro Oncol (2018)

Semiautomated Volumetric Measurement on Postcontrast MR Imaging for Analysis of Recurrent and Residual Disease in Glioblastoma Multiforme

por Chow, D.S., Qi, J., Guo, X., Miloushev, V.Z., Iwamoto, F.M., Bruce, J.N., Lassman, A.B., Schwartz, L.H., Lignelli, A., Zhao, B., Filippi, C.G.
Publicado en AJNR Am J Neuroradiol (2014)

PL3.5 Efficacy and safety of selinexor in recurrent glioblastoma

por Lassman, A B, Wen, P Y, van den Bent, M, Plotkin, S R, Walenkamp, A, Green, A, Huang, X, Karla Rodriguez-Lopez, K, Kauffman, M G, Shacham, S, Mau-Soerensen, M
Publicado en Neuro Oncol (2019)

OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study

por Lassman, A B, Sepúlveda-Sánchez, J M, Cloughesy, T, Gil-Gil, J M, Puduvalli, V K, Raizer, J, De Vos, F Y, Wen, P Y, Butowski, N, Clement, P, Groves, M D, Belda-Iniesta, C, Steward, K, Moran, S, Ye, Y, Roth, P
Publicado en Neuro Oncol (2019)